Jove
Visualize
Contact Us

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation Oncology Opinions and Practice on Cardiotoxicity in Lung Cancer: A Cross-sectional Study by the International Cardio-oncology Society.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

The Association of Incidental Radiation Dose to the Heart Base with Overall Survival and Cardiac Events after Curative-intent Radiotherapy for Non-small Cell Lung Cancer: Results from the NI-HEART Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Assay interference as a cause of false positive troponin T elevation in emergency department patients.

International journal of cardiology·2023
Same author

The Dental Amalgam Phasedown in New Zealand: A 20-year Trend.

Operative dentistry·2020
Same author

Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography.

QJM : monthly journal of the Association of Physicians·2017
Same author

Depression symptom trends and health domains among lung cancer patients in the CanCORS study.

Lung cancer (Amsterdam, Netherlands)·2016
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins: in the beginning.

K S Lyons1, M Harbinson

  • 1Department of Therapeutics and Pharmacology, Queen's University, Belfast. klyons01@qub.ac.uk

The Journal of the Royal College of Physicians of Edinburgh
|June 1, 2010
PubMed
Summary
This summary is machine-generated.

Hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitors, crucial for heart health, have seen significant financial and medical growth since their 1978 human trial. This paper details their development, emphasizing Akira Endo's pivotal contributions.

Related Experiment Videos

Last Updated: Jun 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Pharmacology and Drug Development
  • Biochemistry
  • Cardiovascular Medicine

Background:

  • The development of hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitors, commonly known as statins, began with early research into cholesterol biosynthesis.
  • The first human trial of an HMG CoA reductase inhibitor occurred in 1978, marking a significant milestone in cardiovascular pharmacotherapy.

Discussion:

  • This paper reviews the historical progression and scientific advancements leading to the establishment of HMG CoA reductase inhibitors as a major drug class.
  • It highlights the critical role of researcher Akira Endo in the discovery and initial development of these cholesterol-lowering agents.

Key Insights:

  • Akira Endo's pioneering work was instrumental in identifying and developing HMG CoA reductase inhibitors.
  • The medical and financial impact of this drug class has been substantial since its inception.

Outlook:

  • Continued research into HMG CoA reductase inhibitors may yield further therapeutic applications.
  • Understanding the historical development provides context for future innovations in lipid-lowering therapies.